Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar;133(3):312-5.

Prevalence of multidrug-resistant tuberculosis among category II pulmonary tuberculosis patients

Surendra K Sharma  1 , Sanjeev Kumar, P K Saha, Ninoo George, S K Arora, Deepak Gupta, Urvashi Singh, M Hanif, R P Vashisht
Affiliations

Prevalence of multidrug-resistant tuberculosis among category II pulmonary tuberculosis patients

Surendra K Sharma et al. Indian J Med Res. 2011 Mar.

Abstract

Background & objectives: Multidrug-resistant tuberculosis (MDR-TB) has emerged as a significant global health concern. The most important risk factor for the development of MDR-TB is previous anti-tuberculosis therapy. Category II pulmonary TB includes those patients who had failed previous TB treatment, relapsed after treatment, or defaulted during previous treatment. We carried out this study to ascertain the prevalence of MDR-TB among category II pulmonary TB patients.

Methods: This was a cross-sectional, descriptive study involving category II pulmonary TB patients diagnosed between 2005 and 2008. All sputum-positive category II TB cases were subjected to mycobacterial culture and drug-susceptibility testing (DST). MDR-TB was defined as TB caused by bacilli showing resistance to at least isoniazid and rifampicin.

Results: A total of 196 cases of sputum-positive category II pulmonary tuberculosis patients were included. Of these, 40 patients (20.4%) had MDR-TB. The mean age of MDR-TB patients was 33.25 ± 12.04 yr; 9 patients (22.5%) were female. Thirty six patients showed resistance to rifampicin and isoniazid; while 4 patients showed resistance to rifampicin, isoniazid and streptomycin. The prevalence of MDR-TB among category-II pulmonary tuberculosis patients was 20.4 per cent.

Interpretation & conclusions: The prevalence of MDR-TB in category II TB patients was significant. However, nation-wide and State-wide representative data on prevalence of MDR-TB are lacking. We stress the importance of continuous monitoring of drug resistance trends, in order to assess the efficacy of current interventions and their impact on the TB epidemic.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest We declare that we have no conflict of interest.

Figures

Fig. 1
Fig. 1
Flow chart showing detailed break-up of patients.
See this image and copyright information in PMC

References

    1. Dye C. Global epidemiology of tuberculosis. Lancet. 2006;367:938–40. - PubMed
    1. Corbett EL, Watt CJ, Walker N, Maher D, Williams B, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009–21. - PubMed
    1. Anti-tuberculosis drug resistance in the world; Report no. 4. Geneva, Switzerland: 2010. World Health Organization. WHO/ HTM/TB/2008.394. Available from: http://whqlibdoc.who. int/hq/2008/WHO_HTM_TB_2008.394_eng.pdfaccessed on April 5, 2010.April 5.
    1. Sharma SK, Mohan A. Multidrug-resistant tuberculosis - a menace that threatens to destabilize tuberculosis control. Chest. 2006;130:261–72. - PubMed
    1. Faustini A, Hall A, Perucci C. Risk factors for multi-drug resistant tuberculosis in Europe: a systematic review. Thorax. 2006;61:158–63. - PMC - PubMed

Publication types